MICR-001 / Hofseth Biocare - LARVOL DELTA

Hofseth Biocare ASA: SECOND QUARTER 2021 FINANCIAL REPORT (GlobeNewswire) - "Synthesis of a novel compound for the treatment of eosinophilic (allergic) inflammation such as asthma. A patent has been filed and the process will be completed before year end...The lead analog has shown significantly superior activity to the original molecule (MICR-001) and we are now preparing to carry out pre-clinical trial work. A new PCT patent (US 63/211,972 06/17/2021) has been filed."

Patent • Asthma • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Hofseth Biocare ASA: FIRST QUARTER 2021 FINANCIAL REPORT (GlobeNewswire) - "R&D focus areas in Q1....Completed the synthesis of and invitro assays for 12 novel analog compounds based on our MICR-001 lead structure for asthma/COPD treatment via eosinophilia control. One MICR-001 analog (MA-005) showed superior activity to MICR-001 and is being developed further. New patent filings are being prepared. Recruitment for hospitalized Covid-19 patients in Brazil, Mexico, Hungary and Serbia is on-going."

Preclinical • Trial status • Asthma • Chronic Obstructive Pulmonary Disease • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases